Health Care Cost

The growing utilization of long-acting injectable (LAI) medications for treating patients with schizophrenia indicates a positive trend in mental health practice, according to Brooke Kempf, PMHNP, Indiana University Indianapolis.

The majority of federal savings indicated by the Inflation Reduction Act's Drug Price Negotiation Program can be attributed to 3 drugs.

Changes in formulary coverage for 2024 are impacting Medicare patients' access to and ability to afford various prescription medications.

CDC data from 2021 show the lifetime cost of treating syphilis to be $1190.

Some groups praised CMS after it announced the 10 negotiated Medicare drug prices while others criticized its potential impacts on drug competition and development.

Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by preventing disease progression.

CMS today announced the agreed-upon lower prices for all 10 drugs selected for price negotiations under the Inflation Reduction Act.

Health insurance premiums for 2025 are expected to rise slightly due to higher prescription drug costs and inflation, according to a new analysis from the American Academy of Actuaries.

As the 2024 election approaches, older adults, who comprise more than half of ballots cast, are highly concerned about health care costs, financial scams, and fraud. Concern varies based on gender and political ideology.

While resources and strategies to combat social determinants of health do exist, effectively leveraging them requires a coordinated approach involving supportive policies, technical assistance, community governance, and sustainable financing.

This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.

Medicare Advantage (MA) enrollment has grown to 32.8 million in 2024, representing 54% of total Medicare spending, with significant variation in enrollment across states and counties.

Medicare Advantage beneficiaries with chronic obstructive pulmonary disease (COPD) who were invited to enroll in a program that reduced inhaler costs and provided medication management had higher inhaler adherence; however, there was no significant impact on exacerbations or overall health care spending.

News surrounding different aspects of health insurance shows changes in weight loss treatment coverage, billing and claims processing errors, and customer service utilization.

A rundown of where Minnesota Gov Tim Walz stands on health policy issues and actions he's taken to improve health care.

Experts argue for new mechanisms to fund research in oft-ignored rare diseases.

Hospitals pursue a broad range of efforts to improve quality, with those participating in bundled payments attempting to reduce postacute care to a greater degree than nonparticipants.

The Ochsner-Xavier Institute for Health Equity and Research (OXIHER) is targeting health disparities in Louisiana, focusing on population health management, outcomes research, health careers and equity education, community engagement, and health advocacy and policy.

In the second part of our interview with John M. O'Brien, PharmD, MPH, of the National Pharmaceutical Council (NPC), he calls for further research into employer choices and the influence of benefit consultants in the pharmacy benefit manager (PBM) and drug rebate landscape.

Accessia Health works with advocacy groups to understand specific needs, such as travel assistance, affordable care, and diagnostic testing, ensuring a personalized and human-centered approach to health equity.

New survey data reveals that more than 25% of those aged 50 years and older assume caregiver responsibilities.

Minnesota Gov. Tim Walz has been named as Vice President Kamala Harris' Democratic running mate for the 2024 presidential election and has a proven track record in health care reform.

Real-world cross-validation of insurer and hospital price transparency data finds low overlap but high concordance between data sources.

There will likely be a 7% increase in Affordable Care Act (ACA) Marketplace plan premiums next year across the 324 participating insurers from the 50 states and Washington, DC.

John M. O'Brien, PharmD, MPH, of the National Pharmaceutical Council, discusses his recent study, which sheds light on how important rebates are when choosing benefits for employers and who advises employers on these choices.